Using AI to analyze colon tumors in patients with stage II and III cancer
ATTRACT - ArTificial inTelligence-based RAdiogenomics in Colon Tumors
University of Roma La Sapienza · NCT06108310
This study is testing whether an AI tool can help understand colon tumors better in patients with stage II and III cancer by looking at their scans and genetic information.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Roma La Sapienza (other) |
| Locations | 1 site (Roma, RM) |
| Trial ID | NCT06108310 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to develop an artificial intelligence-based model to assess the radiogenomics signature of colon tumors in patients diagnosed with stage II and III colon cancer. Participants will undergo a preoperative contrast-enhanced CT examination, followed by surgical excision of the tumor and potential adjuvant therapy. The study includes both retrospective and prospective components, utilizing data from 300 patients to identify genetic and radiomics features associated with tumor behavior and prognosis. The AI model will be trained using radiological and genomic data to improve the understanding of tumor aggressiveness and clinical outcomes.
Who should consider this trial
Good fit: Ideal candidates are patients with pathologically confirmed stage II or III colon cancer who have the necessary imaging and biomarker data available.
Not a fit: Patients without preoperative CT images or those with scans affected by motion artifacts may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate predictions of tumor behavior and personalized treatment strategies for colon cancer patients.
How similar studies have performed: Other studies utilizing AI in radiogenomics have shown promise, suggesting that this approach could yield valuable insights, although this specific application is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with pathologically proven stage II and stage III colon cancer; * availability of a CT scan with portal-venous phase at the time of diagnosis; * availability of immunohistochemical panel Exclusion Criteria: * patients with no CT images prior to surgical resection; * patients with CT scans characterized by motion artifacts preventing radiomics analysis
Where this trial is running
Roma, RM
- AOU Sant'Andrea — Roma, RM, Italy (RECRUITING)
Study contacts
- Principal investigator: Andrea Laghi, MD — University of Roma La Sapienza
- Study coordinator: Andrea Laghi, MD
- Email: andrea.laghi@uniroma1.it
- Phone: +390633775285
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Colon Cancer Stage II, Colon Cancer Stage III, colon cancer, artificial intelligence, segmentation, computed tomography